Your browser is no longer supported. Please, upgrade your browser.
ENLV Enlivex Therapeutics Ltd. monthly Stock Chart
ENLV [NASD]
Enlivex Therapeutics Ltd.
Index- P/E- EPS (ttm)-0.83 Insider Own33.52% Shs Outstand13.24M Perf Week-7.97%
Market Cap113.07M Forward P/E- EPS next Y-1.13 Insider Trans0.00% Shs Float7.53M Perf Month-32.49%
Income-9.30M PEG- EPS next Q-0.28 Inst Own13.50% Short Float2.51% Perf Quarter78.66%
Sales- P/S- EPS this Y77.90% Inst Trans-1.87% Short Ratio0.17 Perf Half Y64.23%
Book/sh2.12 P/B4.03 EPS next Y-43.00% ROA- Target Price- Perf Year11.93%
Cash/sh2.12 P/C4.02 EPS next 5Y- ROE- 52W Range3.59 - 16.94 Perf YTD1.77%
Dividend- P/FCF- EPS past 5Y43.80% ROI- 52W High-51.24% Beta1.25
Dividend %- Quick Ratio7.20 Sales past 5Y- Gross Margin- 52W Low130.08% ATR0.82
Employees36 Current Ratio7.20 Sales Q/Q- Oper. Margin- RSI (14)42.03 Volatility5.72% 6.83%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.12 Prev Close8.54
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.10M Price8.26
Recom- SMA20-20.35% SMA50-15.69% SMA20024.37% Volume90,034 Change-3.28%
Nov-18-20 08:00AM  
Nov-17-20 08:18AM  
Nov-11-20 08:14AM  
Nov-05-20 08:30AM  
Nov-03-20 01:44PM  
09:12AM  
Oct-27-20 08:00AM  
Oct-22-20 08:45AM  
Oct-13-20 09:28AM  
Oct-02-20 09:16AM  
Oct-01-20 04:31PM  
09:40AM  
08:18AM  
06:00AM  
Sep-16-20 08:00AM  
Aug-25-20 08:00AM  
Aug-10-20 08:00AM  
Jul-20-20 08:20AM  
Jun-18-20 08:30AM  
Jun-01-20 08:00AM  
May-28-20 08:30AM  
May-20-20 06:56AM  
May-07-20 08:00AM  
Apr-13-20 08:25AM  
Mar-18-20 08:00AM  
Mar-09-20 08:13AM  
Mar-05-20 08:15AM  
Mar-03-20 08:53AM  
Mar-02-20 08:00AM  
Feb-26-20 01:46PM  
Feb-25-20 03:25PM  
Feb-24-20 01:54PM  
08:18AM  
06:30AM  
Feb-20-20 08:38AM  
Nov-21-19 07:30AM  
Nov-20-19 04:14PM  
Nov-18-19 08:30AM  
Nov-12-19 07:30AM  
Nov-05-19 08:42AM  
Nov-04-19 07:30AM  
Oct-30-19 11:55AM  
Oct-24-19 07:30AM  
Oct-10-19 07:30AM  
Oct-08-19 07:30AM  
Oct-07-19 07:30AM  
Sep-23-19 07:30AM  
Sep-09-19 07:30AM  
Sep-04-19 07:30AM  
Aug-19-19 07:30AM  
Aug-01-19 03:50PM  
Jul-16-19 07:30AM  
Jun-18-19 07:30AM  
Jun-06-19 07:30AM  
May-30-19 08:35AM  
Apr-18-19 08:15AM  
Apr-08-19 07:30AM  
Apr-04-19 09:31AM  
Mar-26-19 07:30AM  
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.